



Fig. S1. Proportion of patients with PSSD Symptoms (a) and Signs (b) scores of 0, among patients with Week 16 IGA = 2 (mild psoriasis) after initial treatment with ustekinumab.



[†] Week of randomisation; [‡] Patients with baseline (Week 0) PSSD Symptoms or Signs score > 0; IGA, Investigator's Global Assessment; PSSD, Psoriasis Symptoms and Signs Diary.

Fig. S2. Proportions of patients who achieved absence of individual PSSD symptoms or signs of psoriasis (PSSD scores of 0) at Week 32.



CI, confidence interval; PSSD, Psoriasis Symptoms and Signs Diary.